His scientific interests lie mostly in Microbiology, Antibacterial agent, Ciprofloxacin, Antibiotic resistance and Pharmacology. His studies in Microbiology integrate themes in fields like Ceftazidime and Klebsiella pneumoniae. His Antibacterial agent research incorporates themes from Multiple drug resistance and Drug resistance.
His Antibiotic resistance study combines topics in areas such as Penicillin, Streptococcus pneumoniae and Ceftriaxone. His studies deal with areas such as Minimum inhibitory concentration, Anaerobic bacteria and Avibactam as well as Pharmacology. His work deals with themes such as Cefepime and Imipenem, which intersect with Meropenem.
His primary areas of investigation include Microbiology, Antibacterial agent, Broth microdilution, Antimicrobial and Streptococcus pneumoniae. The concepts of his Microbiology study are interwoven with issues in Pseudomonas aeruginosa and Klebsiella pneumoniae. His research integrates issues of Vancomycin, Minimum inhibitory concentration, Aminoglycoside and Levofloxacin in his study of Antibacterial agent.
His work investigates the relationship between Broth microdilution and topics such as Meropenem that intersect with problems in Colistin and Tigecycline. His Streptococcus pneumoniae study combines topics from a wide range of disciplines, such as Haemophilus influenzae, Virology, Penicillin, Staphylococcus aureus and Ceftriaxone. James A. Karlowsky interconnects Pharmacology and Bacteria in the investigation of issues within Antibiotics.
James A. Karlowsky mainly investigates Microbiology, Broth microdilution, Pseudomonas aeruginosa, Klebsiella pneumoniae and Imipenem. His study in Microbiology is interdisciplinary in nature, drawing from both Bacilli and Escherichia coli. His Broth microdilution study incorporates themes from Ciprofloxacin, Clindamycin, Cefepime, Genotype and Drug resistance.
His work carried out in the field of Pseudomonas aeruginosa brings together such families of science as Multiple drug resistance, Enterobacteriaceae and Intensive care. His research in Klebsiella pneumoniae intersects with topics in Amikacin and Antibiotic resistance, Meropenem. The study incorporates disciplines such as Ceftazidime and Serratia marcescens in addition to Imipenem.
The scientist’s investigation covers issues in Microbiology, Broth microdilution, Pseudomonas aeruginosa, Imipenem and Bacilli. His research in Ceftolozane, Tazobactam, Colistin, Enterococcus and Antimicrobial are components of Microbiology. His biological study spans a wide range of topics, including Sulfamethoxazole, Staphylococcus haemolyticus, Klebsiella pneumoniae and Trimethoprim.
The various areas that he examines in his Imipenem study include Ceftazidime and Multiple drug resistance. James A. Karlowsky has included themes like Acinetobacter baumannii and Pharmacology in his Ceftazidime study. His Bacilli research is multidisciplinary, incorporating elements of Enterobacteriaceae and Cephalosporin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comparative review of the carbapenems.
George G Zhanel;Ryan Wiebe;Leanne Dilay;Kristjan Thomson.
Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of Escherichia coli from Female Outpatients in the United States
James A. Karlowsky;Laurie J. Kelly;Clyde Thornsberry;Mark E. Jones.
Antimicrobial Agents and Chemotherapy (2002)
Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001
James A. Karlowsky;Deborah C. Draghi;Mark E. Jones;Clyde Thornsberry.
Antimicrobial Agents and Chemotherapy (2003)
Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System
Christine Y. Turenne;Steven E. Sanche;Daryl J. Hoban;James A. Karlowsky.
Journal of Clinical Microbiology (1999)
Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000.
Daniel F. Sahm;Clyde Thornsberry;David C. Mayfield;Mark E. Jones.
Antimicrobial Agents and Chemotherapy (2001)
Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002)
Mark E Jones;Deborah C Draghi;Clyde Thornsberry;James A Karlowsky.
Annals of Clinical Microbiology and Antimicrobials (2004)
Review of macrolides and ketolides: focus on respiratory tract infections.
George G. Zhanel;Maria Dueck;Daryl J. Hoban;Lavern M. Vercaigne.
The glycylcyclines: a comparative review with the tetracyclines.
George G Zhanel;Kristen Homenuik;Kim Nichol;Ayman Noreddin.
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
George G. Zhanel;George G. Zhanel;Christopher D. Lawson;Heather Adam;Heather Adam;Frank Schweizer.
Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
George G. Zhanel;Tamiko L. Hisanaga;Nancy M. Laing;Melanie R. DeCorby.
International Journal of Antimicrobial Agents (2006)
Diagnostic Microbiology and Infectious Disease
(Impact Factor: 2.983)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: